Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew R Smith

Showing results (231-240 of 319) with videos related to

Pageof 32
Sort By:
World Journal of Urology|April 17, 2016
Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancerAlex Z Fu, Huei-Ting Tsai, Reina Haque, et al.
The Journal of Urology|December 24, 2016
Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate CancerAlex Z Fu, Huei-Ting Tsai, Reina Haque, et al.
Cell Reports|February 4, 2014
ZFX controls propagation and prevents differentiation of acute T-lymphoblastic and myeloid leukemiaStuart P Weisberg, Matthew R Smith-Raska, Jose M Esquilin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2013
A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastasesRichard J Lee, Philip J Saylor, M Dror Michaelson, et al.
Targeted Oncology|October 2, 2019
Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS TrialNeal Shore, Christian Zurth, Robert Fricke, et al.
Urology|March 13, 2026
The Staging of High-risk And non-metastatic Renal cell carcinoma Preoperatively (SHARP) Model predicts pathologic T3 stage for neoadjuvant clinical trial enrollmentPaz Lotan, Andrew L Wentland, Daniel D Shapiro, et al.
The New England Journal of Medicine|September 9, 2020
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with DarolutamideKarim Fizazi, Neal Shore, Teuvo L Tammela, et al.
European Urology|February 18, 2015
Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up ResultsBertrand Tombal, Michael Borre, Per Rathenborg, et al.
Urologic Oncology|June 11, 2015
Active surveillance for low-risk prostate cancer: Need for intervention and survival at 10 yearsMark A Preston, Adam S Feldman, John J Coen, et al.
European Urology|December 17, 2021
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTANFred Saad, Eric J Small, Felix Y Feng, et al.
Pageof 32

Showing results (231-240 of 319) with videos related to

Sort By:
Pageof 32
World Journal of Urology|April 17, 2016
Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancerAlex Z Fu, Huei-Ting Tsai, Reina Haque, et al.
The Journal of Urology|December 24, 2016
Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate CancerAlex Z Fu, Huei-Ting Tsai, Reina Haque, et al.
Cell Reports|February 4, 2014
ZFX controls propagation and prevents differentiation of acute T-lymphoblastic and myeloid leukemiaStuart P Weisberg, Matthew R Smith-Raska, Jose M Esquilin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2013
A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastasesRichard J Lee, Philip J Saylor, M Dror Michaelson, et al.
Targeted Oncology|October 2, 2019
Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS TrialNeal Shore, Christian Zurth, Robert Fricke, et al.
Urology|March 13, 2026
The Staging of High-risk And non-metastatic Renal cell carcinoma Preoperatively (SHARP) Model predicts pathologic T3 stage for neoadjuvant clinical trial enrollmentPaz Lotan, Andrew L Wentland, Daniel D Shapiro, et al.
The New England Journal of Medicine|September 9, 2020
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with DarolutamideKarim Fizazi, Neal Shore, Teuvo L Tammela, et al.
European Urology|February 18, 2015
Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up ResultsBertrand Tombal, Michael Borre, Per Rathenborg, et al.
Urologic Oncology|June 11, 2015
Active surveillance for low-risk prostate cancer: Need for intervention and survival at 10 yearsMark A Preston, Adam S Feldman, John J Coen, et al.
European Urology|December 17, 2021
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTANFred Saad, Eric J Small, Felix Y Feng, et al.
Pageof 32